Compare CCCC & PAYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | PAYS |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 375.7M |
| IPO Year | 2020 | 2020 |
| Metric | CCCC | PAYS |
|---|---|---|
| Price | $4.17 | $6.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $12.20 | $9.42 |
| AVG Volume (30 Days) | ★ 2.9M | 864.5K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.45 | ★ 85.71 |
| EPS | N/A | ★ 0.09 |
| Revenue | ★ $35,947,000.00 | $24,120,434.00 |
| Revenue This Year | N/A | $33.83 |
| Revenue Next Year | N/A | $14.89 |
| P/E Ratio | ★ N/A | $75.67 |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.36 | $3.08 |
| 52 Week High | $4.60 | $8.88 |
| Indicator | CCCC | PAYS |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 55.72 |
| Support Level | $2.13 | $5.05 |
| Resistance Level | N/A | $7.05 |
| Average True Range (ATR) | 0.37 | 0.42 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 70.09 | 58.27 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.